Background There is widespread concern that treatment with biologic agents may be associated with suboptimal postoperative outcome after surgery for inflammatory bowel diseases (IBD). Aim We aimed to search and analyze the literature regarding the potential association of biologic treatment on adverse postoperative outcome in patients with IBD. We used the subject as a case in point for surgical research. The aim was not to conduct a new systematic review. Method This is an updated narrative review written in a collaborative method by authors invited through Twitter via the following hashtags (#OpenSourceResearch and #SoMe4Surgery). The manuscript was presented as slides on Twitter to allow discussion of each section of the paper sequentially. A Google document was created, which was shared across social media, and comments and edits were verified by the primary author to ensure accuracy and consistency. Results Forty-one collaborators responded to the invitation, and a total of 106 studies were identified that investigated the potential association of preoperative biological treatment on postoperative outcome in patients with IBD. Most of these studies were retrospective observational cohorts: 3 were prospective, 4 experimental, and 3 population-based studies. These studies were previously analyzed in 10 systematic/narrative reviews and 14 meta-analyses. Type of biologic agents, dose, drug concentration, antidrug antibodies, interval between last dose, and types of surgery varied widely among the studies. Adjustment for confounders and bias control ranged from good to very poor. Only 10 studies reported postoperative outcome according to Clavien–Dindo classification. Conclusion Although a large number of studies investigated the potential effect of biological treatment on postoperative outcomes, many reported divergent results. There is a need for randomized controlled trials. Future studies should focus on the avoiding the weakness of prior studies we identified. Seeking collaborators and sharing information via Twitter was integral to widening the contributors/authors and peer review for this article and was an effective method of collaboration.

Biological Treatment and the Potential Risk of Adverse Postoperative Outcome in Patients With Inflammatory Bowel Disease: An Open-Source Expert Panel Review of the Current Literature and Future Perspectives / El-Hussuna, Alaa; Myrelid, Pär; Holubar, Stefan D.; Kotze, Paulo G.; Mackenzie, Graham; Pellino, Gianluca; Winter, Des; Davies, Justin; Negoi, Ionut; Grewal, Perbinder; Gallo, Gaetano; Sahnan, Kapil; Rubio-Perez, Ines; Clerc, Daniel; Demartines, Nicolas; Glasbey, James; Regueiro, Miguel; Sherif, Ahmed E.; Neary, Peter; Pata, Francesco; Silverberg, Mark; Clermont, Stefan; Chadi, Sami A.; Emile, Sameh; Buchs, Nicolas; Millan, Monica; Minaya-Bravo, Ana; Elfeki, Hossam; De Simone Mostafa Shalaby, Veronica; Gutierrez, Celestino; Ozen, Cihan; Yalçınkaya, Ali; Rivadeneira, David; Sturiale, Alssandro; Yassin, Nuha; Spinelli, Antonino; Warusavitarne, Jay; Ioannidis Steven Wexner, Argyrios; Mayol, Julio. - In: CROHN’S & COLITIS 360. - ISSN 2631-827X. - 1:3(2019). [10.1093/crocol/otz021]

Biological Treatment and the Potential Risk of Adverse Postoperative Outcome in Patients With Inflammatory Bowel Disease: An Open-Source Expert Panel Review of the Current Literature and Future Perspectives

Gaetano Gallo;Francesco Pata;
2019

Abstract

Background There is widespread concern that treatment with biologic agents may be associated with suboptimal postoperative outcome after surgery for inflammatory bowel diseases (IBD). Aim We aimed to search and analyze the literature regarding the potential association of biologic treatment on adverse postoperative outcome in patients with IBD. We used the subject as a case in point for surgical research. The aim was not to conduct a new systematic review. Method This is an updated narrative review written in a collaborative method by authors invited through Twitter via the following hashtags (#OpenSourceResearch and #SoMe4Surgery). The manuscript was presented as slides on Twitter to allow discussion of each section of the paper sequentially. A Google document was created, which was shared across social media, and comments and edits were verified by the primary author to ensure accuracy and consistency. Results Forty-one collaborators responded to the invitation, and a total of 106 studies were identified that investigated the potential association of preoperative biological treatment on postoperative outcome in patients with IBD. Most of these studies were retrospective observational cohorts: 3 were prospective, 4 experimental, and 3 population-based studies. These studies were previously analyzed in 10 systematic/narrative reviews and 14 meta-analyses. Type of biologic agents, dose, drug concentration, antidrug antibodies, interval between last dose, and types of surgery varied widely among the studies. Adjustment for confounders and bias control ranged from good to very poor. Only 10 studies reported postoperative outcome according to Clavien–Dindo classification. Conclusion Although a large number of studies investigated the potential effect of biological treatment on postoperative outcomes, many reported divergent results. There is a need for randomized controlled trials. Future studies should focus on the avoiding the weakness of prior studies we identified. Seeking collaborators and sharing information via Twitter was integral to widening the contributors/authors and peer review for this article and was an effective method of collaboration.
2019
Crohn disease; inflammatory bowel disease; ulcerative colitis; biologic treatment; biologics; anti-TNF alpha; postoperative outcome; surgery
01 Pubblicazione su rivista::01a Articolo in rivista
Biological Treatment and the Potential Risk of Adverse Postoperative Outcome in Patients With Inflammatory Bowel Disease: An Open-Source Expert Panel Review of the Current Literature and Future Perspectives / El-Hussuna, Alaa; Myrelid, Pär; Holubar, Stefan D.; Kotze, Paulo G.; Mackenzie, Graham; Pellino, Gianluca; Winter, Des; Davies, Justin; Negoi, Ionut; Grewal, Perbinder; Gallo, Gaetano; Sahnan, Kapil; Rubio-Perez, Ines; Clerc, Daniel; Demartines, Nicolas; Glasbey, James; Regueiro, Miguel; Sherif, Ahmed E.; Neary, Peter; Pata, Francesco; Silverberg, Mark; Clermont, Stefan; Chadi, Sami A.; Emile, Sameh; Buchs, Nicolas; Millan, Monica; Minaya-Bravo, Ana; Elfeki, Hossam; De Simone Mostafa Shalaby, Veronica; Gutierrez, Celestino; Ozen, Cihan; Yalçınkaya, Ali; Rivadeneira, David; Sturiale, Alssandro; Yassin, Nuha; Spinelli, Antonino; Warusavitarne, Jay; Ioannidis Steven Wexner, Argyrios; Mayol, Julio. - In: CROHN’S & COLITIS 360. - ISSN 2631-827X. - 1:3(2019). [10.1093/crocol/otz021]
File allegati a questo prodotto
File Dimensione Formato  
El-Hussuna_Biological-treatment_2019.pdf

accesso aperto

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Creative commons
Dimensione 1.52 MB
Formato Adobe PDF
1.52 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1661811
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 0
social impact